Kira Segal, MD
Ophthalmic Plastic and Reconstructive Surgery · New York, NYNPI 1881960490
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,565 of the $11,941 with a category attached, or 71.7%. Amgen accounts for 98.5% of it on its own, with 6 other manufacturers making up the rest.
Across 65 payments — averaging $183.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$12K
- Genentech USA, Inc.$57
- Tarsus Pharmaceuticals, Inc.$57
- Aerie Pharmaceuticals, Inc.$23
- Sun Pharmaceutical Industries Inc.$19
- Argenx US, Inc.$15
- plus $13 from 1 others
What the payments were for
- Consulting fees$1,76515%
- Speaking & faculty fees$8,56572%
- Food & beverage$1,55013%
- Education$611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 57 | $11,757 |
| Genentech USA, Inc. | 1 | $57 |
| Tarsus Pharmaceuticals, Inc. | 3 | $57 |
| Aerie Pharmaceuticals, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Argenx US, Inc. | 1 | $15 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$10,884
How this compares
$11,941 in reported general payments places this provider in the 75th percentile of 25 ophthalmic plastic and reconstructive surgery providers in New York.
See all ophthalmic plastic and reconstructive surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 24 | $21,802 |
| RestasisCyclosporine | 18 | $11,081 |
| Restasis MultidoseCyclosporine | 15 | $9,470 |
| ErythromycinErythromycin Base | 301 | $3,140 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 61 | $2,424 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 59 | $770 |
| Tobramycin | 14 | $68 |
| Methylprednisolone | 12 | $37 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in New York
- Gary Lelli JrNew York$263K
- James ChelnisNew York$223K
- Anna GinterNew York$2K
- Elizabeth MaherNew York$2K
- Payal PatelNew York$1K
- Kyle GodfreyNew York$824
- Kevin HeinzeNew York$477
- David FreilichNew York$263
- Brett KotlusNew York$194
- I Rand RodgersNew York$45
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.